Over recent years, Prothena has steadily increased its revenue driven by collaborations, yet operating losses have deepened substantially due to escalating research and development expenses typical of clinical-stage biotech firms. Its unique CYTOPE® platform targeting intracellular protein misfolding pathways underpins a diversified pipeline in Parkinson’s, Alzheimer’s, and ATTR amyloidosis, bolstered by key alliances with Roche, Bristol Myers Squibb, and Novo Nordisk. Despite a robust cash position providing runway into the near term, the company must navigate clinical readouts and secure additional financing to sustain its ambitious growth trajectory amid inherent regulatory risks.